Loading stock data…
TNDM
$19.42-0.10 (-0.54%)
Market ClosedLast close May 1
Tandem Diabetes Care, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tandem Diabetes Care, Inc. in the Healthcare sector is trading at $19.42. The stock is currently 35% below its 52-week high of $29.65, remaining 7.8% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why TNDM maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.42
Potential Upside
5%
Whystock Fair Value$20.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Buy
Mean target$31.19+60.6%
Range$20.00 – $56.00
Fundamentals
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-132.40%
Volume
Today's trading volume
1.59M
Recent News
How Investors Are Reacting To Tandem Diabetes Care (TNDM) Expanding Control-IQ+ Use To Type 1 Pregnancies
Tandem Diabetes Care recently received FDA clearance for its Control-IQ+ automated insulin delivery technology to be used during pregnancies complicated by type 1 diabetes, covering both its t:slim X2 and Tandem Mobi systems in the United States. This expanded pregnancy indication, backed by the CIRCUIT trial showing substantially more time in the tight pregnancy glucose range versus standard therapy, widens Tandem’s clinical footprint in a complex, high-need segment of diabetes care. We’ll...
TD Cowen Raises Tandem Diabetes (TNDM) Price Target, Keeps Buy Rating
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, TD Cowen lifted its price target on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) from $25 to $28 and kept its Buy rating on the stock. The firm updated its financial model after Tandem Diabetes Care, Inc. […]
3 Stocks Under $50 Walking a Fine Line
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Weakness
Tandem Diabetes Care (TNDM) is back on investors’ radar after recent share price pressure, with the stock down over the past week, month, and past 3 months. This has prompted closer scrutiny of its fundamentals. See our latest analysis for Tandem Diabetes Care. At a share price of $18.61, Tandem Diabetes Care has faced recent pressure, with the 30 day share price return of a 17.76% decline and a 3 year total shareholder return of a 55.10% loss pointing to fading momentum despite a 10.25% gain...
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration. Markets dislike unpredictability, and these fears were amplified, raising concerns of prolonged conflict and rising oil prices. This negative outlook reflected in consumer confidence, with the University of Michigan's sentiment ind